Helen K Angell

4PUBLICATIONS
45CO-AUTHORS
Predictive and prognostic markersGene and molecular therapyMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Feb 12, 2025
AZD8701, an Antisense Oligonucleotide Targeting FOXP3 mRNA, as Monotherapy and in Combination with Durvalumab: A Phase I Trial in Patients with Advanced Solid Tumors.

Lillian L Siu, Sophie Postel-Vinay, Rafael Villanueva-Vázquez

|Aug 06, 2020
The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy.

Daniela Bruni, Helen K Angell, Jérôme Galon

Pageof 1